Guided Therapeutics (GTHP) Retained Earnings (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Retained Earnings for 16 consecutive years, with -$157.1 million as the latest value for Q4 2025.
- Quarterly Retained Earnings fell 2.18% to -$157.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$157.1 million through Dec 2025, down 2.18% year-over-year, with the annual reading at -$157.1 million for FY2025, 2.18% down from the prior year.
- Retained Earnings hit -$157.1 million in Q4 2025 for Guided Therapeutics, down from -$155.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$140.6 million in Q1 2021 to a low of -$157.1 million in Q4 2025.
- Historically, Retained Earnings has averaged -$149.0 million across 5 years, with a median of -$150.3 million in 2023.
- Biggest five-year swings in Retained Earnings: plummeted 1046546.38% in 2021 and later decreased 1.57% in 2024.
- Year by year, Retained Earnings stood at -$142.4 million in 2021, then fell by 3.49% to -$147.4 million in 2022, then decreased by 2.55% to -$151.1 million in 2023, then dropped by 1.71% to -$153.7 million in 2024, then dropped by 2.18% to -$157.1 million in 2025.
- Business Quant data shows Retained Earnings for GTHP at -$157.1 million in Q4 2025, -$155.8 million in Q3 2025, and -$155.0 million in Q2 2025.